PNTG

Pennant is a well-run, acquisition-driven operator of 172 home health/hospice agencies and 63 senior-living communities. The growth record is genuinely strong and consistent: revenue has more than doubled from $440M (FY2021) to $948M (FY2025), up 36.3% YoY, with net income compounding from $2.7M to $29.6M over the same span. Operating cash flow of $48.3M is real and rising (+22.9%), and the FY2025 acquisition spend (investing outflow of $228M, driven by a $154.7M increase in business/asset acquisitions per the MD&A) shows the roll-up engine is running hard. This is a durable, growing top line in a demographically tailwinded niche.

The problem is that quality of growth and price don't line up. Margins are thin and not expanding — operating margin is just 5.5% and net margin 3.1%, and diluted EPS rose only 20% versus 36% revenue growth, so per-share economics are diluting as the company scales. ROE is a modest 7.9%. Meanwhile the stock trades at 43.3x FY EPS of $0.84, a multiple that prices in flawless continued execution on a 3%-margin business. P/S of 1.3x is more reasonable, but you buy earnings, not sales, and the earnings base is small relative to the market cap.